PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1279911
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1279911
Global Advanced Drug Delivery Systems Market is valued at approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Advanced drug delivery systems (DDS) are technologies designed to optimize the delivery of drugs to their intended site of action in the body. These systems can enhance the efficacy, safety, and convenience of drug therapy by controlling the release, targeting, and localization of the drug. Advanced drug delivery systems offer numerous benefits over traditional drug delivery methods, including improved drug efficacy, reduced side effects, increased patient compliance, and enhanced convenience. They are also being actively researched for their potential to treat a wide range of diseases, including cancer, cardiovascular disease, and neurological disorders. The Advanced Drug Delivery Systems Market is expanding because of factors such as rising diabetes prevalence and prevalence of other diseases, the Development of new drugs and biologics and advancements in understanding human biology and diseases.
The rising prevalence of chronic diseases and cardiac vascular diseases is catering the market growth. according to a 2021 report from the International Diabetes Federation, India had an estimated 74,194.7 thousand cases of diabetes in 2021, and by 2030, that number is predicted to rise to 92,973.7 thousand cases. Furthermore, according to Robert Wood Johnson Foundation, in the year 2020, the incidences of chronic illness in the United States stood at 157 million cases which is projected to increase and reach 171 million cases by the year 2030. Furthermore, Self-injecting devices are becoming increasingly popular, and a significant class of medical devices has also recently arisen from the pipeline of biologics, biosimilars, and auto-injectors. A lot of businesses are concentrating on the introduction of fresh products that will support market expansion. For instance, Agile Therapeutics, Inc. commercially introduce Twirla (levonorgestrel and ethinyl estradiol) transdermal device in the United States in December 2020. Twirla is a new non-daily, non-invasive contraceptive patch. Additionally, in February 2022, Shin-Ya Biotechnology Co., Ltd., a Taiwanese medical wholesaler, placed an order for Nu Gen Medical Devices Inc.'s InsuJet needleless injection system. This is a component of a multi-year sales and distribution deal with an initial minimum commitment of USD 100,000 CDN and subsequent commitments for the following three years. In addition, advancements in Formulation and increased R&D Spending are creating lucrative growth in the market. However, the high cost of Advanced Drug Delivery Systems stifles market growth throughout the forecast period of 2023-2030.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable